Credit Suisse analyst Matt Miksic raised his price target for Edwards Lifesciences to $221 from $189, while reiterating an Outperform rating on the shares. his bullish outlook is based in part on his view that the company does not yet reflect the low-risk expansion of the TAVR market, and investors appear likely to look past Q1 results toward evidence over the next few quarters of increased TAVR growth following the LR data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.